Screener
Vaxcyte, Inc. PCVX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (345,850) | (180,793) |
| Other income, net: | ||
| Interest income | 26,610 | 32,935 |
| Other income (expense) | (1,382) | 7,140 |
| Total other income, net | 25,228 | 40,075 |
| Net loss | $(320,622) | $(140,718) |
| Net loss per share, basic and diluted | $(2.30) | $(1.04) |
| Weighted-average shares outstanding, basic and diluted | 139,506,680 | 135,690,949 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s net income?
- Vaxcyte, Inc. (PCVX) reported net income of -$320.62M in Q1 2026.
- How has Vaxcyte, Inc.'s net income changed year-over-year?
- Vaxcyte, Inc.'s net income decreased by 127.8% year-over-year, from -$140.72M to -$320.62M.
- What is the long-term trend for Vaxcyte, Inc.'s net income?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s net income has grown at a 66.4% compound annual growth rate (CAGR), from -$100.08M to -$766.63M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Vaxcyte, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude